Cardiometabolic research specialist announces Sandrine Claus appointment as Chief Scientific Officer to lead its microbiota-oriented ambitious strategy.

Eligo Bioscience, the French microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured a $20 million Series A round of financing from...

Health for Life Capital is the only non-American investor alongside prestigious strategic and financial investors.

Within thirty months of its creation, MaaT Pharma, a European MicrobioTech1 specialized in the development of innovative treatments based on intestinal microbiota in...

ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, and Nestlé Health Science, announce the joint creation of Microbiome Diagnostics Partners...

Paris, France – July 5, 2017 - Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector,...

Rapidly advancing understanding of the relationship between humans
and their symbiotic microbes, and how their imbalance (dysbiosis) triggers or contributes to...

Enterome SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, is pleased to announce the launch of a Phase 1 clinical study with its...

MaaT Pharma ODYSSEE Study focuses in prevention of dysbiosis complications with autologous fecal microbiota transplantation in Acute Myeloid Leukemia patients undergoing...

Major treatments such as high-dose antibiotic therapies and chemotherapies can lead to serious complications and create a gut microbiota imbalance (formerly called intestinal...